Trial Profile
A retrospective, cohort study to evaluate the long-term outcomes of rituximab therapy patients with ocular ganulomatosis with polyangiitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Granulomatosis
- Focus Therapeutic Use
- 06 Dec 2015 New trial record